Vaccitech Shares Its Progress on a COVID-19 Vaccine

April 20, 2020

BY Alexander Kalis

Bill Enright, CEO of Vaccitech, one of Milltrust’s British Innovation Fund’s investee companies, discusses how the company is helping the fight against COVID-19 through its research in developing a vaccine.

Vaccitech is an investee company of Milltrust’s British Innovation Fund through our early participation in Oxford Sciences Innovation. The company is working on a program supported by the UK Government at the University of Oxford where co-founder Professor Sarah Gilbert has advised that she could be close to delivering a vaccine of a COVID-19 specific vector, and clinical trials are underway with over 500 patients. Vaccitech has a non-exclusive license to this work, and FDA approval is being sought.

A unique element of the work at Vaccitech is the T cell component to protection, which no other research group is measuring. The Vaccitech vaccine is showing significant efficacy in stimulating high levels of T cells needed to protection whereas DNA, RNA and protein-based vaccines do not.

The series A post money valuation of the company was 86 million USD and the company is now seeking a minimum of 55 million USD which will fund the COVID-19 vaccine development, in addition to its other ongoing work, allowing the firm to manufacture tens of millions of doses later this year.

Vaccitech has also promising clinical data from a phase 1 trial for MERS and is scheduled to commence an additional study in Saudi Arabia as soon as travel restrictions permit.

See 6 min webinar summary video below

For more information, please contact [email protected] or visit www.milltrust.com


FOR PROFESSIONAL / QUALIFIED INVESTORS ONLY / NOT FOR PUBLIC DISTRIBUTION Statements attributed to an individual represent the opinions of that individual as of the date published and may not necessarily reflect the view of Milltrust International LLP or its affiliates. Milltrust International LLP uses reasonable efforts to obtain information from third-party sources which it believes to be reliable, Milltrust International LLP makes no representation or warranty as to the accuracy, reliability or completeness of the information. This communication is strictly private and confidential and is issued by Milltrust International LLP, incorporated in the United Kingdom, which is authorised and regulated by the Financial Conduct Authority. Milltrust International LLP has its registered office at 5 Market Yard Mews, 194-204 Bermondsey Street, London, SE1 3TQ, United Kingdom and is a subsidiary of Milltrust International Group (Singapore) Pte Ltd. None of the investment products mentioned herein are regulated collective investment schemes for the purposes of the UK Financial Services and Markets Act 2000. The promotion of such products and the distribution of this document are, accordingly, restricted by law. Most of the protections provided by the UK regulatory system and compensation under the UK’s Financial Services Compensation Scheme will not be available. The investments described herein are only available to investors permitted to invest in the prospectus of the fund and are not available to private investors. The nature of the fund investments carries certain risks and the Fund may utilise investment techniques which may carry additional risk. The value of investments and the income from them may fall as well as rise and is not guaranteed. Past performance is not a reliable indicator of future performance. This document contains forward-looking statements which are correct as at the date of this document. Such statements involve known and unknown risks, uncertainties and other important factors that could cause actual results, performance or projections to be materially different from future results. Any investment in the funds mentioned above should be based on the full details contained in the relevant prospectus and supplements which are available from www.milltrust.com. Notice to US investors: the shares of Milltrust International Managed Investments ICAV and Milltrust International Investments SPC have not been registered under the 1933 Securities Act or under the 1940 Act; however the company takes advantage of the 3[C]7 exemption and shares are available to 3[C](1) US qualified purchasers and those qualifying under Reg D distribution activity in the US is undertaken by Silverleaf Partners LLC, a registered broker-dealer based in New York.